Human epididymis protein 4 (HE4): a potential biomarker for IPF

S. Jo (Waltham, United States of America), J. Winkler (New Haven, United States of America), A. Sullivan (Waltham, United States of America), L. Luus (Waltham, United States of America), E. Herzog (New Haven, United States of America), A. Ray (Waltham, United States of America)

Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers
Session: Chronic lung diseases: novel methods, diagnostics and biomarkers
Session type: E-poster session
Number: 327
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Jo (Waltham, United States of America), J. Winkler (New Haven, United States of America), A. Sullivan (Waltham, United States of America), L. Luus (Waltham, United States of America), E. Herzog (New Haven, United States of America), A. Ray (Waltham, United States of America). Human epididymis protein 4 (HE4): a potential biomarker for IPF. 327

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Development of a new sensitive ELISA for the determination in serum of uteroglobin-related protein 1 (UGRP-1), a new potential lung biomarker
Source: Annual Congress 2010 - Innovations in the assessment of airway diseases
Year: 2010


WFDC2 (HE4) and SLPI are differentially expressed in normal and diseased human lung and in lung cancer
Source: Annual Congress 2006 - Molecular airway biology
Year: 2006


The detection of quantitative serum p53 protein in lung cancer and its clinical value
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003

Cancer-associated oncogenic BARD1 isoforms: From biomarker expression studies to development of a blood test for early detection of lung cancer
Source: Annual Congress 2012 - Early detection of lung cancer
Year: 2012

Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D
Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease
Year: 2009

Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021


Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008


Investigation of possible role of serum fibulin as biomarker of COPD.
Source: Virtual Congress 2020 – Mechanistic insight into lung injury and repair
Year: 2020


Prognostic significance of plasma D-dimer (DD) in lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 72s
Year: 2002

Pregnancy-associated plasma protein A (PAPP-A) and lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008

Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019

Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012


Identification of genes with diagnostic and prognostic value in lung cancer.
Source: International Congress 2019 – Biology of lung cancer
Year: 2019


Nuclear expression of Y-Box binding protein (YB-1) as a negative prognostic marker in non-small cell lung cancer
Source: Annual Congress 2003 - Lung cancer biology
Year: 2003


KL-6 is a useful serum biomarker for early detection of interstitial lung disease
Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Year: 2012


Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
Source: Eur Respir J 2015; 46: 1773-1780
Year: 2015



Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer?
Source: Eur Respir J 2004; 24: Suppl. 48, 77s
Year: 2004

Circulating biomarkers and tumour molecular profiling in patients with non-small cell lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015

Serum napsin A is a novel diagnostic and monitoring marker for interstitial lung disease
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011

Independent validation of prognostic value of 22 microRNAs (miRs) in stage I-II lung adenocarcinoma (AC)
Source: Annual Congress 2012 - New mechanisms in non-neoplastic and neoplastic lung diseases
Year: 2012